![](/img/cover-not-exists.png)
42PRibociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC)
Masuda, N, Noguchi, S, Ishikawa, T, Aruga, T, Kim, S J, Toyama, T, Saeki, T, Saito, M, Yamanaka, T, Watanabe, J, Nakamura, S, Takahashi, M, Inoue, K, Gounaris, I, Han, Y, Samant, T S, Gazdoiu, M, Ito,Volume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy428.003
Date:
November, 2018
File:
PDF, 93 KB
2018